Specifications
- Purity
- ≥98% (HPLC)
- Appearance
- White to off-white powder
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO (20 mg/ml), ethanol (10 mg/ml)
Available from stock
Sertraline hydrochloride
- SKU
- S0088
Categories:
- Synonyms
- (1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride , CP 51,974-1 , Lustral , Seserine , Zoloft
- 79559-97-0
- CAS-Number
- C17H17NCl2 · HCl
- Molecular Formula
- 342.69
- Molecular Weight
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
- Shipping
- AMBIENT
- Short Term Storage
- -20°C
- Long Term Storage
- -20°C
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at -20°C.
- Hazard statements
- H302-H400
- Precautionary statements
- P301 + P312 + P330
- GHS Symbol
- GHS07+GHS09
- Signal word
- Warning
- RIDADR
- 3077 9
- Transportation
- Packing Group III
- Description
- Sertraline is a tetraline that inhibits monoamine transporters and acts as a potent highly selective serotonin reuptake inhibitor (SSRI), with affinity for the serotonin transporter (SERT), increasing availability of serotonin (5-hydroxytryptamine, 5-HT) in the brain and leading to antidepressant, anxiolytic and antiobsessional effects. Sertraline binds also to the dopamine transporter (DAT) and the sigma ?1 receptor (but not the ?2 receptor) with 100-fold lower affinity. It acts as an antagonist of the ?1 receptor, and is able to reverse ?1 receptor-dependent actions of fluvoxamine, a potent agonist of the receptor, in vitro. Sertraline displays antiproliferative activity on human colorectal carcinoma cells.
- Smiles
- CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl.Cl
- InChi Key
- BLFQGGGGFNSJKA-XHXSRVRCSA-N
- References
- (1) B.K. Koe, et al., J. Pharmacol. Exp. Ther. 226, 686 (1983) , (2) W.M. Welch, et al., J. Med. Chem. 27, 1508 (1984) , (3) J. Heym & B.K. Koe, J. Clin. Psychiatry 49, 40 (1988) , (4) M. Tatsumi, et al., Eur. J. Pharmacol. 340, 249 (1997) , (5) G. MacQueen, et al., CNS Drug Reviews 7, 1 (2001) , (6) H.R. Khouzam, et al., Compr. Ther. 29, 47 (2003) , (7) J.H. Meyer, et al., Am. J. Psych. 161, 826 (2004) , (8) B. Lowe, et al., J. Affect. Disord. 87, 271 (2005) , (9) Y. Albayrak & K. Hashimoto, Adv. Exp. Med. Biol. 964, 153 (2017)
Sertraline is a tetraline that inhibits monoamine transporters and acts as a potent highly selective serotonin reuptake inhibitor (SSRI), with affinity for the serotonin transporter (SERT), increasing availability of serotonin (5-hydroxytryptamine, 5-HT) in the brain and leading to antidepressant, anxiolytic and antiobsessional effects. Sertraline binds also to the dopamine transporter (DAT) and the sigma ?1 receptor (but not the ?2 receptor) with 100-fold lower affinity. It acts as an antagonist of the ?1 receptor, and is able to reverse ?1 receptor-dependent actions of fluvoxamine, a potent agonist of the receptor, in vitro. Sertraline displays antiproliferative activity on human colorectal carcinoma cells.
Additional information
| Synonyms | (1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride, CP 51,974-1, Lustral, Seserine, Zoloft |
|---|---|
| Purity | ≥98% (HPLC) |
| Appearance | White to off-white powder |
| CAS-Number | 79559-97-0 |
| Molecular Formula | C17H17NCl2 · HCl |
| Molecular Weight | 342.69 |
| Identity | 1H-NMR |
| Solvents | DMSO (20 mg/ml), ethanol (10 mg/ml) |
| Smiles | CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl.Cl |
| InChi Key | BLFQGGGGFNSJKA-XHXSRVRCSA-N |
| Shipping | AMBIENT |
| Short Term Storage | -20°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Hazard statements | H302-H400 |
| Precautionary statements | P301 + P312 + P330 |
| GHS Symbol | GHS07+GHS09 |
| Signal word | Warning |
| RIDADR | 3077 9 |
| Transportation | Packing Group III |
| References | (1) B.K. Koe, et al., J. Pharmacol. Exp. Ther. 226, 686 (1983), (2) W.M. Welch, et al., J. Med. Chem. 27, 1508 (1984), (3) J. Heym & B.K. Koe, J. Clin. Psychiatry 49, 40 (1988), (4) M. Tatsumi, et al., Eur. J. Pharmacol. 340, 249 (1997), (5) G. MacQueen, et al., CNS Drug Reviews 7, 1 (2001), (6) H.R. Khouzam, et al., Compr. Ther. 29, 47 (2003), (7) J.H. Meyer, et al., Am. J. Psych. 161, 826 (2004), (8) B. Lowe, et al., J. Affect. Disord. 87, 271 (2005), (9) Y. Albayrak & K. Hashimoto, Adv. Exp. Med. Biol. 964, 153 (2017) |
| Quantity | 10 mg, 50 mg, Bulk |
